CLAIMS

1. An aqueous ophthalmic composition for prevention or treatment of dry eye, comprising diquafosol or a salt thereof and polyvinylpyrrolidone filled in a multidoe-type eye drop container, wherein the amount of the aqueous ophthalmic composition to be filled is 1 to 10 mL.

2. The aqueous ophthalmic composition according to claim 1, further comprising a silver salt.

3. The aqueous ophthalmic composition according to claim 2, wherein the silver salt comprises silver nitrate.

~~4. The aqueous ophthalmic composition according to any one of claims 1 to 3, wherein the aqueous ophthalmic composition is for prevention or treatment of dry eye.~~

~~5~~4. The aqueous ophthalmic composition according to claim ~~4~~1, comprising diquafosol sodium at a concentration of 1 to 5% (w/v) and polyvinylpyrrolidone having a K value of more than 30 and 120 or less.

~~6~~5. The aqueous ophthalmic composition according to claim ~~4~~1, comprising diquafosol sodium at a concentration of 3% (w/v) and polyvinylpyrrolidone having a K value of more than 30 and 120 or less.

~~7~~6. The aqueous ophthalmic composition according to claim ~~4~~1, comprising diquafosol sodium at a concentration of 1 to 5% (w/v) and having a viscosity at 25°C of 1.5 to 30 mPa·s.

~~8~~7. The aqueous ophthalmic composition according to claim ~~4~~1, comprising

diquafosol sodium at a concentration of 3% (w/v) and having a viscosity at 25°C of 1.5 to 30 mPa·s.

~~9~~8. The aqueous ophthalmic composition according to any one of claims ~~5~~1 to ~~8~~7, wherein the aqueous ophthalmic composition is used so as to be instilled into the eye 2 to 4 times a day.

~~10~~9. The aqueous ophthalmic composition according to any one of claims ~~5~~1 to ~~8~~7, wherein the aqueous ophthalmic composition is used so as to be instilled into the eye 3 times a day.

~~11~~10. The aqueous ophthalmic composition according to claim ~~9~~8 or ~~10~~9, wherein the aqueous ophthalmic composition is used so as to be instilled into the eye in a dose of 1 to 2 drops each time.

~~12. An ophthalmic medicament product comprising 0.1 to 1 mL of the aqueous ophthalmic composition according to claim 1 filled in a unit dose-type eye drop container.~~

~~13. An ophthalmic medicament product comprising 0.3 to 0.5 mL of the aqueous ophthalmic composition according to claim 1 filled in a unit dose-type eye drop container.~~

~~14~~11. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 1 to 10 mL of ~~the~~an aqueous ophthalmic composition comprising diquafosol or a salt thereof and polyvinylpyrrolidone ~~according to any one of claims 1 to 3~~ filled in a multidose-type eye drop container.

~~15~~12. An ophthalmic medicament product for prevention or treatment of dry

eye, comprising 5 mL of ~~the~~an aqueous ophthalmic composition comprising diquafosol or a salt thereof and polyvinylpyrrolidone~~according to any one of claims 1 to 3~~ filled in a multidose-type eye drop container.

~~16~~13. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 1 to 10 mL of ~~the~~an aqueous ophthalmic composition comprising diquafosol or a salt thereof and polyvinylpyrrolidone ~~according to claim 1~~ filled in a PFMD container.

~~17~~14. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 5 mL of ~~the~~an aqueous ophthalmic composition comprising diquafosol or a salt thereof and polyvinylpyrrolidone ~~according to claim 1~~ filled in a PFMD container.

~~18. The ophthalmic medicament product according to any one of claims 12 to 17, wherein the ophthalmic medicament product is for prevention or treatment of dry eye.~~

~~19~~15. The ophthalmic medicament product according to any one of claims ~~18~~11 to 14, wherein the aqueous ophthalmic composition comprises diquafosol sodium at a concentration of 1 to 5% (w/v) and polyvinylpyrrolidone having a K value of more than 30 and 120 or less.

~~20~~16. The ophthalmic medicament product according to any one of claims ~~18~~11 to 14, wherein the aqueous ophthalmic composition comprises diquafosol sodium at a concentration of 3% (w/v) and polyvinylpyrrolidone having a K value of more than 30 and 120 or less.

~~21~~17. The ophthalmic medicament product according to any one of claims

~~18~~11 to 14, wherein the aqueous composition comprises diquafosol sodium at a concentration of 1 to 5% (w/v) and has a viscosity at 25°C of 1.5 to 30 mPa·s.

~~22~~18. The ophthalmic medicament product according to any one of claims ~~18~~11 to 14, wherein the aqueous composition comprises diquafosol sodium at a concentration of 3% (w/v) and has a viscosity at 25°C of 1.5 to 30 mPa·s.

~~23~~19. The ophthalmic medicament product according to any one of claims ~~19~~11 to ~~22~~18, wherein the ophthalmic medicament product is used so as to be instilled into the eye 2 to 4 times a day.

~~24~~20. The ophthalmic medicament product according to any one of claims ~~19~~11 to ~~22~~18, wherein the ophthalmic medicament product is used so as to be instilled into the eye 3 times a day.

~~25~~21. The ophthalmic medicament product according to claim ~~23~~19 or ~~24~~20, wherein the ophthalmic medicament product is used so as to be instilled into the eye in a dose of 1 to 2 drops each time.

~~26~~22. The aqueous ophthalmic composition according to any one of claims 1 to ~~4~~3, comprising polyvinylpyrrolidone having a K value of 17 or more.

~~27~~23. The aqueous ophthalmic composition according to any one of claims 1 to ~~4~~3, comprising polyvinylpyrrolidone having a K value of 17 to 120.

~~28~~24. The aqueous ophthalmic composition according to any one of claims 1 to ~~4~~3, comprising polyvinylpyrrolidone having a K value of more than 30 and 120 or less.

~~29~~25. The aqueous ophthalmic composition according to any one of claims 1 to ~~4~~3, comprising polyvinylpyrrolidone having a K value of 90 or more.

~~30~~26. The aqueous ophthalmic composition according to any one of claims 1 to ~~11~~10, wherein the concentration of the polyvinylpyrrolidone is 0.001% (w/v) or more.

~~31~~27. The aqueous ophthalmic composition according to any one of claims 1 to ~~4~~3, wherein the concentration of the diquafosol or a salt thereof is 0.0001 to 10% (w/v).

~~32~~28. The aqueous ophthalmic composition according to any one of claims 1 to ~~4~~3, wherein the concentration of the diquafosol or a salt thereof is 0.01 to 5% (w/v).

~~33~~29. The aqueous ophthalmic composition according to any one of claims 1 to ~~4~~3, wherein the concentration of the diquafosol or a salt thereof is 1 to 5% (w/v).

~~34~~30. The aqueous ophthalmic composition according to any one of claims 1 to ~~4~~3, wherein the concentration of the diquafosol or a salt thereof is 3% (w/v).

~~35~~31. The aqueous ophthalmic composition according to any one of claims 1 to ~~11~~10, wherein the aqueous ophthalmic composition has a pH in the range of 6 to 8.

~~36~~32. The aqueous ophthalmic composition according to any one of claims 1 to ~~11~~10, wherein the aqueous ophthalmic composition has a pH in the range of 7 to 8.

~~37~~33. The aqueous ophthalmic composition according to any one of claims 1 to ~~11~~10, wherein the aqueous ophthalmic composition is a sterile aqueous ophthalmic solution.

~~38~~34. The aqueous ophthalmic composition according to any one of claims 1 to ~~11~~10, wherein the aqueous ophthalmic composition is preservable at room temperature.

~~39~~35. The aqueous ophthalmic composition according to any one of claims 1 to ~~6~~5, wherein the aqueous ophthalmic composition has a viscosity at 25°C of 1.5 to 30 mPa·s.

~~40~~36. The aqueous ophthalmic composition according to any one of claims 1 to ~~4~~3, wherein the salt of diquafosol is diquafosol sodium.

~~41~~37. An aqueous ophthalmic composition for prevention or treatment of dry eye, comprising diquafosol sodium at a concentration of 3% (w/v), polyvinylpyrrolidone having a K value of 90, and silver nitrate, wherein the aqueous ophthalmic composition is used so as to be instilled into the eye 2 to 4 times a day in a dose of 1 or 2 drops each time.

~~42~~38. An aqueous ophthalmic composition for prevention or treatment of dry eye, comprising diquafosol sodium at a concentration of 3% (w/v), polyvinylpyrrolidone, and silver nitrate, the aqueous ophthalmic composition being used so as to be instilled into the eye 2 to 4 times a day in a dose of 1 or 2 drops each time, wherein the aqueous ophthalmic composition has a viscosity at 25°C of 3 to 30 mPa·s.

~~43~~39. The aqueous ophthalmic composition according to claim ~~41~~37 or ~~42~~38, wherein the aqueous ophthalmic composition is used so as to be instilled into the eye 3 times a day.

~~44. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 0.1 to 1 mL of an aqueous ophthalmic composition filled in a unit dose-type eye drop container, the aqueous ophthalmic composition comprising diquafosol sodium at a concentration of 3% (w/v) and polyvinylpyrrolidone having a K value of 90, wherein the aqueous ophthalmic composition is used so as to be instilled into the eye 2 to 4 times a day in a dose of 1 or 2 drops each time.~~

~~45. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 0.1 to 1 mL of an aqueous ophthalmic composition filled in a unit dose-type eye drop container, the aqueous ophthalmic composition comprising diquafosol sodium at a concentration of 3% (w/v) and polyvinylpyrrolidone, wherein the aqueous ophthalmic composition has a viscosity at 25°C of 3 to 30 mPa·s and is used so as to be instilled into the eye 2 to 4 times a day in a dose of 1 or 2 drops each time.~~

~~46~~40. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 1 to 10 mL of an aqueous ophthalmic composition filled in a multidose-type eye drop container, the aqueous ophthalmic composition comprising diquafosol sodium at a concentration of 3% (w/v) and polyvinylpyrrolidone having a K value of 90, wherein the aqueous ophthalmic composition is used so as to be instilled into the eye 2 to 4 times a day in a dose of 1 or 2 drops each time.

~~47~~41. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 1 to 10 mL of an aqueous ophthalmic composition filled in a multidose-type eye drop container, the aqueous ophthalmic composition comprising diquafosol sodium at a concentration of 3% (w/v) and polyvinylpyrrolidone, wherein the aqueous ophthalmic composition has a viscosity at 25°C of 3 to 30 mPa·s and is used so as to be instilled into the eye 2 to 4 times a day in a dose of 1 or 2 drops each time.

~~48~~42. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 1 to 10 mL of an aqueous ophthalmic composition filled in a PFMD container, the aqueous ophthalmic composition comprising diquafosol sodium at a concentration of 3% (w/v) and polyvinylpyrrolidone having a K value of 90, wherein the aqueous ophthalmic composition is used so as to be instilled into the eye 2 to 4 times a day in a dose of 1 or 2 drops each time.

~~49~~43. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 1 to 10 mL of an aqueous ophthalmic composition filled in a PFMD container, the aqueous ophthalmic composition comprising diquafosol sodium at a concentration of 3% (w/v) and polyvinylpyrrolidone, wherein the aqueous ophthalmic composition has a viscosity at 25°C of 3 to 30 mPa·s and is used so as to be instilled into the eye 2 to 4 times a day in a dose of 1 or 2 drops each time.

~~50~~44. The ophthalmic medicament product according to any one of claims ~~44~~40 to ~~49~~43, wherein the ophthalmic medicament product is used so as to be instilled into the eye 3 times a day.

~~51~~45. The ophthalmic medicament product according to any one of claim ~~46~~40 or ~~47~~41, further comprising silver nitrate.